TREM-2 is cleaved by microglia to produce soluble TREM-2, whose levels are reportedly increased in CSF of patients with relapsing-remitting, secondary progressive, and primary progressive MS, being normalized by treatment with the immunomodulatory drug natalizumab (Öhrfelt et al., 2016). The gene discussed is TREM2; the disease is primary progressive multiple sclerosis.